Navigation Links
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Date:6/16/2008

these new approaches into clinical medicine."

"We are gratified for the opportunity to work jointly with Fox Chase Cancer Center and Olympus Corporation to develop the first clinical applications of our fluorescence molecular imaging technology platforms," said Kirtland Poss, President and CEO of VisEn Medical. "This program is a major step forward in VisEn Medical's central mission, which is to lead the development and commercialization of fluorescence in vivo imaging technologies in a range of translational applications from research through clinical medicine, enabling substantial benefits for researchers, pharmaceutical companies, doctors and patients."

Both Dr. Seiden and Mr. Poss noted the contributions to the project by Olympus Medical Systems Corp. "We are pleased to receive the system support from Olympus Medical Systems Corp. through their provision of these novel fluorescence imaging systems into the program," said Mr. Poss. "These advances will help open up new opportunities for more effective and efficient cancer detection, surgery and treatment."

The ProSense(R) Activatable Imaging Agent platform was developed to provide in vivo readouts of some of the key protease activities known to underlie disease states in oncology, inflammation, and cardiovascular disease. A pre-clinical version of ProSense is currently being used by leading academic institutions and pharmaceutical customers worldwide to image disease-related in vivo protease profiles in pre-clinical research and drug development. The IND program and the planned Phase I clinical trials are designed to translate the benefits of ProSense into humans, as well as to further develop the multi-channel white light and near infrared fluorescence laparoscopic imaging systems used in collecting and analyzing fused images in real time in the operating room. The planned trial is also designed to gather safety and imaging data for the agent, which will be administered systemically, and to
'/>"/>

SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
2. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
5. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
6. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
7. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
8. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
9. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
10. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... today announced that executives of the company will address ... Sachs CEO Unplugged Conference on Jan. 6 at ... New York. 28th Annual J.P. Morgan Healthcare ... the Westin St. Francis Hotel in San Francisco. ... Health,s diverse products and services, company performance and strategies ...
(Date:12/14/2009)... Dec. 14 Greenway Medical ... integrated EHR, Prime Suite (®) ... 2011 Ambulatory EHR, additionally certified for Child ... Reporting. Greenway,s Prime Suite 2011 achieved ... certification designations offered by the Certification Commission ...
(Date:12/14/2009)... -- Cardium Therapeutics (NYSE Amex: CXM ) ... GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers," ... Industry Conference held December 10-13, 2009 in St. ... attended by top industry leaders and renowned researchers ... Dr. Barbara K. Sosnowski, Cardium,s Vice President of ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 3Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 4Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4Scientists discover gene module underlying atherosclerosis development 10995 1Scientists discover gene module underlying atherosclerosis development 10995 2How nutrition affects healthy aging 10992 1How nutrition affects healthy aging 10992 2Miami Dentist Dr H A Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 62601 1Miami Dentist Dr H A Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 62601 2
... than 70 abstracts highlight VELCADE efficacy in broad ... CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, ... leading therapy with unsurpassed single-agent,efficacy for patients with ... the upcoming International Myeloma,Workshop (IMW) in Kos, Greece, ...
... Describes Identification, Characterization and Broad,Neuroprotective Properties of ... , Neurodegenerative Disease Specialists Publish Details of ... Mitochondrial Proteins , MARSEILLE, June 19th, 2007 ... the discovery and development of drugs for,neurological ...
Other Medicine Technology:Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 2Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 3Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 4
(Date:12/14/2009)... Krause, an aerospace engineer,for NASA, was giving the ... he,was confident that technology and science could solve ... one thing that science couldn,t solve.,His wife Susan ... machines,would keep her alive for awhile, she would ... 69 and is starting dialysis next month. She ...
(Date:12/14/2009)... could be linked to scans performed in 2007 , , ... are exposing patients to far more radiation than previously thought ... cancers a year, two new studies claim. , Based on ... Archives of Internal Medicine , the study authors, joined ... calling on clinicians to limit radiation exposure to patients. , ...
(Date:12/14/2009)... , , MONDAY, Dec. 14 (HealthDay News) -- Here,s good ... a cup or two of java: Coffee and tea ... diabetes. , That,s the conclusion of an Australian ... the lower your risk of diabetes. Every cup of ... the risk of diabetes, the researchers said. , ...
(Date:12/14/2009)... are linked to an increased risk of certain cancers. ... synthetic insulin preparation marketed under the trade name Lantus), ... cancers than other insulins or oral glucose lowering medications. ... important factors such as obesity that may have driven ... large randomized trial designed to examine another aspect of ...
(Date:12/14/2009)... COPD, researchers say , , MONDAY, Dec. 14 (HealthDay News) ... lung function, a finding that may help lead to ... of researchers compared lung function with genetic variants at ... genome in more than 20,000 people of European ancestry. ... variants associated with alterations in lung function. , The ...
Breaking Medicine News(10 mins):Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2
... Medicine Cabinet Day Set For Saturday October 13,Proper ... OTC Drug Abuse, CHICAGO, Oct. 8 ... treatment to adolescents, adults and their,families, said today ... an area wide "Clean Out Your Medicine Cabinet" ...
... men who have surgery for prostate cancer appear less likely ... who choose other treatment options, especially if they are younger ... a report in the Oct. 8 issue of Archives of ... treatments are still being debated because they have not yet ...
... Center researcher has been awarded a National Institutes of ... factors, in addition to traditional predictors, can be useful ... disease. , Kevin A. Fiscella, M.D., M.P.H., associate professor ... by the National Heart, Lung and Blood Institute, part ...
... Study finds it outperforming other forms of treatment , ... the best chance of long-term survival for prostate cancer ... University found that prostate cancer patients who had surgery ... 10 years than men who had other types of ...
... of Parkinson,s patients more likely to develop dementia, study ... Relatives of people with Parkinson,s disease face up to ... suggests a new study that says genetics could be ... of the central nervous system, such as impaired motor ...
... WASHINGTON, Oct. 8 Crowell & Moring LLP ... Rhoad to the firm,s,Health Care and False Claims ... represents both health care and government contract clients,in ... Claims Act,(FCA), antitrust claims, and criminal and civil ...
Other Medicine News:Health News:Rosecrance and Chicago's Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs 2Health News:Rosecrance and Chicago's Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs 3Health News:Swiss study suggests surgery may offer best chance of long-term prostate cancer survival 2Health News:Study to consider social risk in guiding prevention of heart disease 2Health News:Surgery Best Bet for Prostate Cancer Survival 2Health News:Parkinson's Linked to Risk of Alzheimer's 2Health News:Crowell & Moring's Expanding Health Care Litigation Practice Gains Experienced Litigator 2Health News:Crowell & Moring's Expanding Health Care Litigation Practice Gains Experienced Litigator 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: